Fetch.ai’s Ethereum contract is under an ongoing attack, according to monitoring data from Blockaid. The security firm said the incident was still unfolding at the time of its disclosure, with total losses estimated at about $2.01 million. Of that amount, roughly $1.56 million in FET was stolen from a token conversion contract, while another $452,000 in NTX was maliciously minted. Blockaid said the attacker exploited a valid conversion authorization signature in the conversionIn function of TokenConversionManagerV3. Using that signature, the attacker was able to drain the remaining FET inventory held in the converter. The same attacker wallet then went on to mint a large amount of NTX from the NuNet deployer account. The disclosure points to two separate asset impacts within the same incident: stolen FET and newly minted NTX. No additional remediation details, recovery measures, or final loss figures were provided in the source at the time of publication.

PANews’ latest daily roundup spans market calls, security incidents, project updates, regulation and whale activity across crypto. Among the headline items, analyst PlanB said Bitcoin has moved above its 50-week moving average at about $79,000 and is now targeting the 100-week moving average near $89,000, arguing that the bear market has ended. On the equities side, Cointelegraph reported that MicroStrategy, trading as MSTR, was the best-performing Nasdaq-100 component over the past month with a 48% gain. The report also covered a major fraud case in Istanbul involving more than $3 billion, where authorities arrested 191 suspects in a cross-agency operation. In the U.S., Kalshi and Kraken parent Payward filed applications tied to perpetual contracts linked to individual stocks. Project-side developments included Universal’s planned wind-down over 60 days, MultiversX pausing its mainnet after confirming an attack attempt, and a dispute between Chengming Technology and Zhipu over alleged unauthorized data uploads by the ZCode client. Security and on-chain data featured heavily as well. Forbes reported that North Korea-linked hackers infected more than 30,000 devices through fake job offers and stole data from over 7,000 crypto wallets, with at least $10.71 million flowing to attacker-controlled wallets. PANews also highlighted losses at Fetch.ai and NuNet, several large leveraged positions, and comments from Michael Saylor, Vitalik Buterin, Peter Schiff, Jiang Zhuoer and ZachXBT.

Fetch.ai said on Sept. 20 that it has published an on-chain analysis report on its recent exploit incident, tracing the attack from a compromised signing key through to the wallet addresses allegedly used by the attacker to cash out funds. The project said the report is not its final analysis and that the investigation is still ongoing. Fetch.ai also said it worked with SingularityNET to disable the affected wallets and contracts tied to the incident. The team added that more updates will be released as the investigation progresses. The disclosure follows earlier reports that a hacker targeted both Fetch.ai and NuNet, causing combined crypto losses of about $2 million. In Fetch.ai’s case, 8.7 million FET, worth about $1.53 million, was transferred out. At NuNet, 408.5 million NTX was minted, with an estimated value of about $462,700.

Fetch.ai said on X that it is aware of reports that its token conversion contract was attacked and that its team is investigating the incident, with an update to follow as soon as possible. Earlier, Foresight News reported that a Fetch.ai Ethereum contract was under ongoing attack, with estimated losses of about $2.01 million. Of that total, roughly $1.56 million in FET was reported stolen from the token conversion contract, while another roughly $452,000 in NTX was said to have been maliciously minted. The company’s statement did not provide further technical details or a timeline for the next update, but it confirmed that an internal review is underway.

PeckShield said the same attacker exploited both Fetch.ai and NuNet, with combined crypto losses of about $2 million. In Fetch.ai’s case, 8.7 million FET worth about $1.53 million were moved out. At NuNet, 408.5 million NTX were minted, with an estimated value of about $462,700. PeckShield also said NTX had fallen about 65% as of the latest update. The attacker has already swapped the stolen funds into 546.36 ETH, worth roughly $1.44 million, according to the monitoring firm. The figures were cited by BlockBeats in a Sept. 20 report.

Onchain Lens said it has tracked an attack cluster that moved about $1.54 million worth of FET from Fetch AI’s token converter on Ethereum. The same cluster also received roughly $452,000 in newly minted NTX from the Nunet Global deployer. Based on the activity identified so far, the confirmed amount involved stands at about $2.01 million. The alert points to two separate token flows linked to the same cluster: one involving FET from Fetch AI’s Ethereum-based converter, and another involving newly minted NTX sent from the Nunet Global deployer. No further details on the wallets or subsequent fund movements were provided in the brief update cited by ChainCatcher.

Binance said it will adjust the leverage and margin tiers for 11 USDⓈ-M perpetual contracts at 14:30 UTC+8 on Aug. 28, 2026, according to an official notice cited by Odaily. The contracts affected are FILUSDT, ROBOUSDT, LPTUSDT, ZRXUSDT, SPORTFUNUSDT, NOMUSDT, SAGAUSDT, QNTXUSDT, SHAZUSDT, STRCUSDT, and BSPUSDT. Binance said the update is expected to be completed within one hour. Existing positions will be affected, and the exchange advised users to make adjustments in advance. The notice did not include additional details in the brief.

Moderna and Merck said their jointly developed mRNA melanoma vaccine trial met its goal, setting off a sharp rally in biopharma stocks. Moderna shares surged as much as 176.97% on Wednesday and closed at $174, marking the company’s biggest single-day gain on record, according to ABMedia. Merck also rose more than 12.60% to $152.20. The report said the vaccine candidate, Intismeran Autogene, used in combination with Merck’s Keytruda, reduced the risk of recurrence for some melanoma patients. Leerink Partners analyst Daina Graybosch called the Phase 3 trial result “historic.” ABMedia also said the move lifted shares of BioNTech, AbbVie, Amgen, Eli Lilly and Johnson & Johnson. The outlet added that Moderna’s latest progress came after weaker COVID-19 vaccine demand had left investors watching its transition strategy closely, while recent sector rotation had started bringing capital back into healthcare and biotech stocks.